Sean Saint, Co-Founder and CEO of Companion Medical Named One of the Top 50 Healthcare Technology CEOs of 2020

Sean Saint, co-founder and CEO of Companion Medical, the producers of InPen, the only FDA-cleared reusable smart insulin pen system, has been named as one of the Top 50 Healthcare Technology CEOs of 2020 by The Healthcare Technology Report.

As a leader in the development of easy-to-use, affordable insulin technology, Companion Medical was founded by people with diabetes which propels their drive for continuous innovation and product development. Companion Medical’s mission is to create groundbreaking solutions that drastically improve the lives of people living with Type 1 and Type 2 diabetes.

“I never really intended to start Companion Medical. After I was diagnosed with Type 1 in 2011, I started doing the research and realized that there were no other companies providing advanced technology and insulin intelligence to the millions of people with diabetes who decide not to be tethered to an insulin pump,” explained Sean Saint, CEO and co-founder of Companion Medical. “While most other insulin-delivery companies are focused on the small minority of people who want – or can afford – to use a pump, we decided to focus on helping the vast majority of people by providing them the same insulin insights plus the freedom of an affordable, smart insulin pen. We had to do this.”

Companion Medical’s InPen is the only FDA-cleared, smart insulin pen system that combines a reusable, Bluetooth insulin pen and an intuitive mobile app that helps users take the right insulin dose, at the right time. With a custom dose calculator, dosing reminders and the ability to see active insulin, InPen takes the guesswork out of managing diabetes.

“Now more than ever, with our global community impacted by this severe pandemic, the importance of the healthcare technology field is at the forefront. An extensive process was run to evaluate the hundreds of CEOs who were nominated this year. These CEOs lead exemplary organizations in the fields of medical devices, biotech, healthcare analytics, healthcare software and other related areas,” said Jerald Hapitan, editor of The Healthcare Technology Report. “We gathered data on each nominee’s professional background and assessed them across several key areas including breadth of leadership experience in the healthcare technology industry, level of expertise and domain knowledge in their particular field, depth of their executive team’s experience, and consistency of organizational performance. The Healthcare Technology Report is pleased to announce The Top 50 Healthcare Technology CEOs of 2020.”

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.